Basima A Almomani1, Wail A Hayajneh2,3, Abeer M Ayoub4, Mera A Ababneh4, Miral A Al Momani2,3. 1. Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan. baalmomani1@just.edu.jo. 2. Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan. 3. Department of Pediatrics and Neonatology, King Abdullah University Hospital, Irbid, Jordan. 4. Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
Abstract
PURPOSE: To assess incidence rate, risk factors and susceptibility patterns associated with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae in community-acquired urinary tract infections (CA-UTIs). METHODS: A prospective, case-control study was conducted at a tertiary teaching hospital from Jan 2015 to Dec 2016. The results of microbiology cultures were initially screened to include only patients with positive E. coli or K. pneumoniae urine cultures. Afterwards, clinical symptoms were assessed to confirm the UTI. To investigate the risk factors, patients with a positive urine culture for ESBL-producing isolates were assigned as cases, while patients with non-ESBL were assigned as controls. RESULTS: Out of 591 patients included in this study, 57.5% (n = 340) were included in the control group and 42.5% (n = 251) were in the case group. The incidence rate of ESBL-producing isolates was 3.465 cases per 1000-patient hospital admissions. Male gender (OR = 1.856, 95% CI = 1.192-2.889, p = 0.006), pediatrics (OR = 1.676, 95% CI = 1.117-2.517, p = 0.013), patients with comorbidity (OR = 1.542, 95% CI = 1.029-2.312, p = 0.036) and UTI in the previous 12 months (OR = 1.705, 95% CI = 1.106-2.628, p = 0.016) were independently associated with a higher risk of infection. The resistance rate for most commonly prescribed antibiotics was high. CONCLUSIONS: Our results suggest that the incidence of ESBL producers among CA-UTIs is high. Male gender, pediatrics, comorbidity and UTI in the previous 12 months were associated with a higher risk for infection. Continuous surveillance and prudent antibiotic use by healthcare professionals are important factors for effective control of ESBL associated infections.
PURPOSE: To assess incidence rate, risk factors and susceptibility patterns associated with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae in community-acquired urinary tract infections (CA-UTIs). METHODS: A prospective, case-control study was conducted at a tertiary teaching hospital from Jan 2015 to Dec 2016. The results of microbiology cultures were initially screened to include only patients with positive E. coli or K. pneumoniae urine cultures. Afterwards, clinical symptoms were assessed to confirm the UTI. To investigate the risk factors, patients with a positive urine culture for ESBL-producing isolates were assigned as cases, while patients with non-ESBL were assigned as controls. RESULTS: Out of 591 patients included in this study, 57.5% (n = 340) were included in the control group and 42.5% (n = 251) were in the case group. The incidence rate of ESBL-producing isolates was 3.465 cases per 1000-patient hospital admissions. Male gender (OR = 1.856, 95% CI = 1.192-2.889, p = 0.006), pediatrics (OR = 1.676, 95% CI = 1.117-2.517, p = 0.013), patients with comorbidity (OR = 1.542, 95% CI = 1.029-2.312, p = 0.036) and UTI in the previous 12 months (OR = 1.705, 95% CI = 1.106-2.628, p = 0.016) were independently associated with a higher risk of infection. The resistance rate for most commonly prescribed antibiotics was high. CONCLUSIONS: Our results suggest that the incidence of ESBL producers among CA-UTIs is high. Male gender, pediatrics, comorbidity and UTI in the previous 12 months were associated with a higher risk for infection. Continuous surveillance and prudent antibiotic use by healthcare professionals are important factors for effective control of ESBL associated infections.
Authors: L S Briongos-Figuero; T Gómez-Traveso; P Bachiller-Luque; M Domínguez-Gil González; A Gómez-Nieto; T Palacios-Martín; M González-Sagrado; A Dueñas-Laita; J L Pérez-Castrillón Journal: Int J Clin Pract Date: 2012-09 Impact factor: 2.503
Authors: T Goulenok; A Ferroni; E Bille; H Lécuyer; O Join-Lambert; P Descamps; X Nassif; J-R Zahar Journal: J Hosp Infect Date: 2013-07-08 Impact factor: 3.926
Authors: E Yilmaz; H Akalin; S Ozbey; Y Kordan; M Sinirtaş; E Gürcüoglu; C Ozakin; Y Heper; R Mistik; S Helvaci Journal: J Chemother Date: 2008-10 Impact factor: 1.714
Authors: M M P S C Fernando; W A N V Luke; J K N D Miththinda; R D S S Wickramasinghe; B S Sebastiampillai; M P M L Gunathilake; F H D S Silva; R Premaratna Journal: BMC Infect Dis Date: 2017-02-10 Impact factor: 3.090
Authors: Sima L Sharara; Joe Amoah; Zoi D Pana; Patricia J Simner; Sara E Cosgrove; Pranita D Tamma Journal: Clin Infect Dis Date: 2020-11-05 Impact factor: 9.079